Stryker has now twice defeated Treace's antitrust claims at the pleading stage, significantly reducing the risk of a disruptive bundling challenge. However, patent infringement claims remain pending, and Treace may seek leave to amend again. Monitor for any third amended complaint or summary judgment motions on the patent counts.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $311.07entry
- T+1 · 4mo ago +1.73%α +1.33% · $316.44
- T+5 · 4mo ago +1.13%α +1.60% · $314.58
- T+20 · 3mo ago +11.92%α +9.43% · $348.15
- T+60 · 6w ago −11.47%α −14.84% · $275.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stryker won dismissal of Treace Medical's antitrust (Sherman Act, Clayton Act, state antitrust) and tortious interference claims without prejudice, marking the second time the court has rejected these counts at the pleading stage. The ruling removes the immediate threat of treble damages and injunctive relief from Stryker's bundling practices, though patent infringement claims remain pending.
Court Ruling Details
Key Facts
- Court granted Stryker's motion to dismiss Counts XIII–XVI (antitrust and tortious interference) without prejudice.
- Antitrust claims dismissed for failure to plead antitrust injury, allegations were conclusory and only showed harm to Treace, not to competition in the TMT bunion systems market.
- Tortious interference claim dismissed because it was based on the same alleged anticompetitive conduct as the antitrust counts.
- This is the second dismissal of these claims; the original complaint was dismissed in October 2025.
- Patent infringement claims (Counts I–XII) remain active and were not addressed in this ruling.
Financial Impact
Dismissal of antitrust and tortious interference claims removes potential treble damages and injunctive relief exposure; patent claims remain pending with unknown damages exposure.
Risk Factors
- Treace may file a second amended complaint with more specific antitrust allegations, potentially reviving the dismissed counts.
- Patent infringement claims (Counts I–XII) remain pending and could result in damages or injunctive relief if Stryker is found to infringe.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-889e1f0a26-SYK |
Track record
29 reports on SYK
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
- Nov 9, 20268d ago 8-K Neutral 2/10 Entry $324.29 Now $310.72 −4.18% settles Dec 9
- Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
- Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
- Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
- Oct 29, 202619d ago 8-K Bearish 6/10 No price data
- Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
- Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
- Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
- Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers